| 2026-10-26 17:14 |
8-K |
["1.01", "1.02", "2.03"] |
other |
0.25
|
West Pharmaceutical refinanced credit facility; boilerplate M&A language suggests financing flexibility but no active transaction. |
SEC · detail |
| 2026-07-23 07:14 |
8-K |
["2.02", "7.01", "9.01"] |
other |
0.05
|
Routine earnings announcement with no M&A signals, activist involvement, or strategic transaction indicators. |
SEC · detail |
| 2026-07-14 16:29 |
8-K |
["1.01", "9.01"] |
material agreement |
0.05
|
Routine renewal of technology exchange and distribution agreements with minority-owned partner Daikyo; no M&A indicators. |
SEC · detail |
| 2026-06-01 16:32 |
8-K |
["5.02"] |
officer change |
0.15
|
CEO succession announcement with new hire from Thermo Fisher; routine leadership transition, not M&A-related. |
SEC · detail |
| 2026-05-20 16:04 |
8-K |
["1.05", "9.01"] |
other |
0.00
|
8-K/A amendment disclosing material cybersecurity incident with no M&A implications. |
SEC · detail |
| 2026-05-11 17:06 |
8-K |
["1.05", "7.01", "9.01", "99.1"] |
other |
0.00
|
Material cybersecurity incident disclosure; no M&A signals present. |
SEC · detail |
| 2026-05-05 16:49 |
8-K |
["5.07", "9.01"] |
other |
0.05
|
Routine 8-K reporting 2026 Annual Meeting voting results and auditor ratification. No M&A signals. |
SEC · detail |